Phase 3 Thyroid Cancer Trial, Recruiting NCT06554652 Sponsor: Fudan University Condition: Thyroid Cancer
Back to Thyroid Cancer

Phase 3 Thyroid Cancer Trial, Recruiting

NCT06554652
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with papillary thyroid cancer (a specific type of thyroid cancer), confirmed by laboratory testing of tissue samples
  • People between the ages of 14 and 80
  • People whose lymph node biopsy (a procedure using a thin needle) before surgery has confirmed that cancer has spread to lymph nodes on the side of the neck
  • People whose ultrasound and CT scans show that affected or possibly affected lymph nodes are found only in a specific zone of the neck (called compartment IV), with only 1–2 affected lymph nodes, each measuring less than 1cm across, and showing no signs of tissue breakdown or blockage in surrounding areas (confirm with trial site)
  • People whose thyroid cancer has not grown beyond the thyroid gland itself
  • People whose thyroid gland is large enough to allow an injection of a tracking substance during the procedure

Who may not be able to join:

  • People who have previously had surgery on their neck
  • People who have had lymph nodes removed from both sides of the neck
  • People whose cancer has spread to distant parts of the body
  • People whose cancer is classified as a higher-risk type, or who have other specific factors that increase the risk of the cancer returning (confirm with trial site)
  • People who have previously received treatment for thyroid cancer other than hormone therapy
  • People who would not be able to attend or participate in follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 November 2024
Est. completion
30 June 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Local-regional Recurrence Free Survival,LRFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov